Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
AIMS: Elevated non-fasting triglycerides mark elevated levels of remnant cholesterol. Using a Mendelian randomization approach, we tested whether genetically increased remnant cholesterol in hypertriglyceridaemia due to genetic variation in the apolipoprotein A5 gene (APOA5) associates with an increased risk of myocardial infarction (MI). METHODS AND RESULTS: We resequenced the core promoter and coding regions of APOA5 in individuals with the lowest 1% (n = 95) and highest 2% (n = 190) triglyceride levels in the Copenhagen City Heart Study (CCHS, n = 10 391). Genetic variants which differed in frequency between the two extreme triglyceride groups (c.-1131T > C, S19W, and c.*31C > T; P-value: 0.06 to <0.001), thus suggesting an effect on triglyceride levels, were genotyped in the Copenhagen General Population Study (CGPS), the CCHS, and the Copenhagen Ischemic Heart Disease Study (CIHDS), comprising a total of 5705 MI cases and 54 408 controls. Genotype combinations of these common variants associated with increases in non-fasting triglycerides and calculated remnant cholesterol of, respectively, up to 68% (1.10 mmol/L) and 56% (0.40 mmol/L) (P < 0.001), and with a corresponding odds ratio for MI of 1.87 (95% confidence interval: 1.25-2.81). Using APOA5 genotypes in instrumental variable analysis, the observational hazard ratio for a doubling in non-fasting triglycerides was 1.57 (1.32-2.68) compared with a causal genetic odds ratio of 1.94 (1.40-1.85) (P for comparison = 0.28). For calculated remnant cholesterol, the corresponding values were 1.67(1.38-2.02) observational and 2.23(1.48-3.35) causal (P for comparison = 0.21). CONCLUSION: These data are consistent with a causal association between elevated levels of remnant cholesterol in hypertriglyceridaemia and an increased risk of MI. Limitations include that remnants were not measured directly, and that APOA5 genetic variants may influence other lipoprotein parameters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [62]
In the citing paper
“Epidemiological and Mendelian randomization studies have also pointed toward a causal role of elevated triglycerides in atherosclerosis due to an elevation of remnant cholesterol particles (7-9).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Elevated triglycerides are associated with an increase in remnant cholesterol, a decrease in high-density lipoprotein cholesterol (HDL-C), and an increase in LDL particles with a change in morphology to small, dense particles.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Recent systematic studies comparing fasting and non-fasting samples have suggested that the difference is small for most lipid parameters [85,94-100].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [94]
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [76]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Antman, E., Bassand, J.-P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., Simoons, M., & Tendera, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00804-4 · Cited by 4,821
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943 · cited 1×
“Furthermore, recent studies have suggested that the cholesterol efflux capacity from macrophages, a possible metric of HDL function, is a more reliable marker of cardiovascular risk than plasma levels of HDL cholesterol.(55) In line with this, there is until now no basis on which to link the cholesterol content of HDL…”
BackgroundTriglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationAn Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716 · cited 2×
“C associated with triglyceride levels in a dose-dependent manner and with a corresponding increase in cardiovascular risk.(30) Combining three genetic variants into 10 genotype combinations in the largest study to date, we show that the combined genotypes are associated with stepwise increases in non-fasting triglycer…”
BackgroundResultLangsted, A., Freiberg, J. J., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.108.804146 · Cited by 588
Self-citationGriffin, B. A., Freeman, D. J., Tait, G. W., Thomson, J., Caslake, M. J., Packard, C. J., & Shepherd, J. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90129-5 · Cited by 525
Frikke-Schmidt, R. (2008) · JAMA · doi:10.1001/jama.299.21.2524 · Cited by 464
Self-citationNordestgaard, B. G., Wootton, R., & Lewis, B. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.4.534 · Cited by 334
Self-citationPCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
Benn, M., Nordestgaard, B. G., Grande, P., Schnohr, P., & Tybjærg-Hansen, A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.044 · Cited by 314
Self-citationSchaap, F. G., Rensen, P. C. N., Voshol, P. J., Vrins, C., van der Vliet, H. N., Chamuleau, R. A. F. M., Havekes, L. M., Groen, A. K., & van Dijk, K. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403240200 · Cited by 300
Merkel, M., Loeffler, B., Kluger, M., Fabig, N., Geppert, G., Pennacchio, L. A., Laatsch, A., & Heeren, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411412200 · Cited by 291
Haase, C. L., Tybjærg-Hansen, A., Ali Qayyum, A., Schou, J., Nordestgaard, B. G., & Frikke-Schmidt, R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1846 · Cited by 282
Self-citationAustin, M. A., McKnight, B., Edwards, K. L., Bradley, C. M., McNeely, M. J., Psaty, B. M., Brunzell, J. D., & Motulsky, A. G. (2000) · Circulation · doi:10.1161/01.cir.101.24.2777 · Cited by 255
Increased Lipoprotein-Remnant Formation in Chronic Renal Failure
Nestel, P. J., Fidge, N. H., & Tan, M. H. (1982) · New England Journal of Medicine · doi:10.1056/nejm198208053070601 · Cited by 240
Langsted, A., Freiberg, J. J., Tybjaerg-Hansen, A., Schnohr, P., Jensen, G. B., & Nordestgaard, B. G. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02333.x · Cited by 230
Self-citationShaikh, M., Wootton, R., Nordestgaard, B. G., Baskerville, P., Lumley, J. S., La Ville, A. E., Quiney, J., & Lewis, B. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.3.569 · Cited by 206 · cited 1×
“share with LDL the potential to enter and get trapped in the intima of the arterial wall.(9,10,31) This would lead to intimal accumu-”
BackgroundSelf-citationLai, C.-Q., Demissie, S., Cupples, L. A., Zhu, Y., Adiconis, X., Parnell, L. D., Corella, D., & Ordovas, J. M. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400192-jlr200 · Cited by 163
Nordestgaard, B. G., Tybjaerg-Hansen, A., & Lewis, B. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.1.6 · Cited by 159
Self-citationPlasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60312-2 · Cited by 148
Self-citationLai, C., Tai, E. S., Tan, C. E., Cutter, J. L., Chew, S. K., Zhu, Y., Adiconis, X., & Ordovás, J. M. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300251-jlr200 · Cited by 138
HDL-C: Role as a risk modifier
Barter, P. J. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70885-6 · Cited by 135
Szalai, C., Keszei, M., Duba, J., Prohászka, Z., Kozma, G. T., Császár, A., Balogh, S., Almássy, Z., Füst, G., & Czinner, A. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.12.003 · Cited by 126
Clinical Relevance of Postprandial Lipaemia
Kolovou, G. D., Anagnostopoulou, K. K., Daskalopoulou, S. S., Mikhailidis, D. P., & Cokkinos, D. V. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054546609 · Cited by 123
Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population
Varbo, A., Nordestgaard, B. G., Tybjærg‐Hansen, A., Schnohr, P., Jensen, G. B., & Benn, M. (2011) · Annals of Neurology · doi:10.1002/ana.22384 · Cited by 122
Self-citationAPOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease
Talmud, P. J., Martin, S., Taskinen, M., Frick, M. H., Nieminen, M. S., Kesäniemi, Y. A., Pasternack, A. I., Humphries, S. E., & Syvänne, M. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300458-jlr200 · Cited by 114
Wittrup, H. H., Tybjærg‐Hansen, A., Abildgaard, S., Steffensen, R., Schnohr, P., & Nordestgaard, B. G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119323 · Cited by 114
Self-citationNonfasting Hyperlipidemia and Cardiovascular Disease
Nordestgaard, B. G., Langsted, A., & Freiberg, J. (2009) · Current Drug Targets · doi:10.2174/138945009787846434 · Cited by 113
Self-citationApolipoprotein A-V Interaction with Members of the Low Density Lipoprotein Receptor Gene Family
Nilsson, S. K., Lõokene, A., Beckstead, J. A., Gliemann, J., Ryan, R. O., & Olivecrona, G. (2007) · Biochemistry · doi:10.1021/bi7000533 · Cited by 105
Haase, C. L., Tybjærg-Hansen, A., Grande, P., & Frikke-Schmidt, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0450 · Cited by 104
Self-citationJohannsen, T. H., Kamstrup, P. R., Andersen, R. V., Jensen, G. B., Sillesen, H. H., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1342 · Cited by 99
Self-citationVaessen, S. F. C., Schaap, F. G., Kuivenhoven, J. A., Groen, A. K., Hutten, B. A., Boekholdt, S. M., Hattori, H., Sandhu, M. S., Bingham, S. A., Luben, R., et al. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600233-jlr200 · Cited by 95
Lee, K. W. J., Ayyobi, A. F., Frohlich, J. J., & Hill, J. S. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.04.024 · Cited by 82
Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency
Santos, R. D., Schaefer, E. J., Asztalos, B. F., Polisecki, E. Y., Wang, J., Hegele, R. A., Martinez, L. R. C., Miname, M. H., Rochitte, C. E., da Luz, P. L., et al. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700362-jlr200 · Cited by 70
Martinelli, N., Trabetti, E., Bassi, A., Girelli, D., Friso, S., Pizzolo, F., Sandri, M. F., Malerba, G., Pignatti, P. F., Corrocher, R., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.04.009 · Cited by 69
Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834477d2 · Cited by 64
Self-citationOliva, C. P., Carubbi, F., Schaap, F. G., Bertolini, S., & Calandra, S. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01912.x · Cited by 64
Liu, H., Zhang, S., Lin, J., Li, H., Huang, A., Xiao, C., Li, X., Su, Z., Wang, C., Nebert, D. W., et al. (2005) · Metabolism · doi:10.1016/j.metabol.2004.11.009 · Cited by 55
Jang, Y., Paik, J. K., Hyun, Y. J., Chae, J. S., Kim, J. Y., Choi, J. R., Lee, S., Shin, D.-J., Ordovás, J. M., & Lee, J. H. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.12.024 · Cited by 52
Dallongeville, J., Cottel, D., Montaye, M., Codron, V., Amouyel, P., & Helbecque, N. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2004.10.065 · Cited by 52
Mutations in thelipoprotein lipaseGene Associated With Ischemic Heart Disease in Men
Wittrup, H. H., Tybjærg‐Hansen, A., Steffensen, R., Deeb, S. S., Brunzell, J. D., Jensen, G. B., & Nordestgaard, B. G. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.6.1535 · Cited by 47
Self-citationEffect of gender on phenotypic expression of the S447X mutation in LPL
Wittrup, H. H., Nordestgaard, B. G., Steffensen, R., Jensen, G. B., & Tybjærg‐Hansen, A. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00183-1 · Cited by 45
Self-citationKasama, T., Yoshino, G., IWATANI, I., Iwai, M., Hatanaka, H., Kazumi, T., Oimomi, M., & Baba, S. (1987) · Atherosclerosis · doi:10.1016/0021-9150(87)90130-4 · Cited by 45
Nakajima, K., Nakano, T., Moon, H. D., Nagamine, T., Stanhope, K. L., Havel, P. J., & Warnick, G. R. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.03.051 · Cited by 41
Research works printed but not linked: 1
- 2001, Type III hyperlipoproteinemia (dyslipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 2835
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-17
- Volume
- 34
- Issue
- 24
- Pages
- 1826-1833
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2040770080
- Cited by
- 501
- References
- 60
- Citations by year
- 2026: 28 · 2025: 53 · 2024: 48 · 2023: 40 · 2022: 51 · 2021: 45 · 2020: 41 · 2019: 39 · 2018: 26 · 2017: 34 · 2016: 31 · 2015: 30 · 2014: 20 · 2013: 11
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- remnant cholesterol, hypertriglyceridemia, myocardial infarction, APOA5, genetic variants, causal risk factors, remnant lipoproteins, Copenhagen City Heart Study, Copenhagen General Population Study, instrumental variables, Mendelian randomization
- MeSH terms
- Apolipoprotein A-V, Adult, Aged, Aged, 80 and over, Apolipoproteins A, Cholesterol, Female, Genotype, Humans, Lipoproteins, Male, Middle Aged, Myocardial Infarction, Promoter Regions, Genetic, Prospective Studies, Risk Factors, Triglycerides, Hypertriglyceridemia, Linkage Disequilibrium, Case-Control Studies, Polymorphism, Single Nucleotide, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.